Loading...
NYSE: ZTS
Zoetis Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
●S&P 500 since 2013
Market Cap
$51.73B
52w High
$172.23
52w Low
$114.47
P/E
19.24
Volume
5.12M
Outstanding Shares
440.69M
Company profile
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally.
CEOKristin C. Peck
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees13,800
IPO dateFeb 1, 2013
Valuation
Forward P/E—
EV/EBITDA15.48
Enterprise value$62.97B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth3.02%
Gross margin70.49%▲2.01%vs FY2024
Operating margin38%▲3.68%vs FY2024
ROE80.25%▲53.97%vs FY2024
Analyst consensus
RatingHold
Target price$143.86▲22.56%
15
Buy
15
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$1.76
$1.62
Q3FY25
ActualEst.
$1.70
$1.62
Q4FY25
ActualEst.
$1.48
$1.40
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$2.46B
$2.41B
Q3FY25
ActualEst.
$2.4B
$2.41B
Q4FY25
ActualEst.
$2.39B
$2.36B
Q1FY26
Next Est.
—